DAFTAR PUSTAKA

Adam, R., Aloia, T., Krissat, J., Bralet, M.-P., Paule, B., Giacchetti, S., Delvart, V., Azoulay, D., Bismuth, H., & Castaing, D. (2006). Is Liver Resection Justified for Patients With Hepatic Metastases From Breast Cancer? *Annals of Surgery*, *244*(6), 897–908. https://doi.org/10.1097/01.sla.0000246847.02058.1b

Adson, M. A. (1987). Resection of liver metastases—When is it worthwhile? *World Journal of Surgery*, *11*(4), 511–520. https://doi.org/10.1007/BF01655817

Albrecht, T., Hohmann, J., Oldenburg, A., Skrok, J., & Wolf, K. J. (2004). Detection and characterisation of liver metastases. *European Radiology Supplements*, *14*(S8), P25–P33. https://doi.org/10.1007/s10406-004-0088-z

American Cancer Society. (2020). *Liver Metastases*. Cancer.Org. https://www.cancer.org/treatment/understanding-your-diagnosis/advanced-cancer/liver-metastases.html

American Cancer Society. (2019). Breast cancer. *Breast Cancer Facts & Figures 2019-2020*, 1–32.

Anggorowati.(2013). Faktor Resiko Kanker Payudara Wanita.KEMAS 8 (2) (2013) 121-126.Diakses tanggal 17 Desember 2013 time 19.20.

Bale, R., Putzer, D., & Schullian, P. (2019). Local Treatment of Breast Cancer Liver Metastasis. *Cancers*, *11*(9), 1341. https://doi.org/10.3390/cancers11091341

Ballantyne, G. H., & Quin, J. (1993). Surgical treatment of liver metastases in patients with colorectal cancer. *Cancer*, *71*, 4252–4266. https://doi.org/https://doi.org/10.1002/1097-0142(19930615)71:12+<4252::AID-CNCR2820711815>3.0.CO;2-6

Bray, F., Ferlay, J., & Soerjomataram, I. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinnicians*, *68*, 394–424. https://doi.org/10.3322/caac.21492

Breast Cancer Now. (2021). *Secondary breast cancer in the liver*.

Breastcancernow.Org. https://breastcancernow.org/information-support/facing-breast-cancer/secondary-metastatic-breast-cancer/secondary-breast-cancer-in-liver

Brookes, M., MacVicar, D., Husband, J., 2007. Metastatic carcinoma of the breast: The appearances of metastatic spread to the abdomen and pelvis as demonstrated by CT. *Br. J. Radiol.* 80: 284–292. doi:10.1259/bjr/50066770

Brown, L., Muhm, & Gray, J. (1980). Radiographic detection of thymoma. *American Journal of Roentgenology*, *134*(6), 1181–1188. https://doi.org/10.2214/ajr.134.6.1181

Cancello, G., Maisonneuve, P., Rotmensz, N., Viale, G., Mastropasqua, M. G., Pruneri, G., Montagna, E., Iorfida, M., Mazza, M., Balduzzi, A., Veronesi, P., Luini, A., Intra, M., Goldhirsch, A., & Colleoni, M. (2013). Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. *Annals of Oncology*, *24*(3), 661–668. https://doi.org/10.1093/annonc/mds430

Chang, J., Clark, G. M., Allred, D. C., Mohsin, S., Chamness, G., & Elledge, R. M. (2003). Survival of patients with metastatic breast carcinoma. *Cancer*, *97*(3), 545–553. https://doi.org/10.1002/cncr.11083

Chen, Q. W., Li, H. J., Chen, Y. N., Ning, Z. Y., Gao, S., Shen, Y. H., Meng, Z. Q., Vargulick, S., Wang, B. Y., & Chen, H. (2016). Hepatic Lesions Detected after Mastectomy, in Breast Cancer Patients with Hepatitis Background May Need to Undergo Liver Biopsy to Rule Out Second Primary Hepatocellular Carcinoma. *PloS one*, *11*(1),

Centeno B. A. (2006). Pathology of liver metastases. *Cancer control : journal of the Moffitt Cancer Center*, *13*(1), 13–26. https://doi.org/10.1177/107327480601300103

Colditz, G. A. (2019) *Breast Cancer Epidemiology and Risk Factors*. Available at: https://emedicine.medscape.com/article/1697353-overview (Accessed: 28 August 2021).

Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009). Pattern of metastatic spread in triple-negative breast cancer. *Breast Cancer Research and Treatment*, *115*(2), 423–428. https://doi.org/10.1007/s10549-008-0086-2

Desiyani, Nani. 2009. Analisis Faktor-Faktor Yang Berhubungan Dengan Kejadian Kanker Payudara Di Rumah Sakit Pertamina Cilacap.Jurnal

Keperawatan Soedirman (The Soedirman Journal of Nursing), Volume 4, No.2 Juli 2009 hal 61-66.Diakses tanggal 13 Maret 2014 time 11.30.

Dwi Wahyuning Anggarini *, and Anita Rahmawati **, and Margono, (2018) *HUBUNGAN PENGGUNAAN KONTRASEPSI HORMONAL DENGAN KEJADIAN KANKER PAYUDARA DI RSUP DR. SARDJITO YOGYAKARTA*. UNSPECIFIED thesis, Poltekkes Kemenkes Yogyakarta.

Duan XF, Dong NN, Zhang T, Li Q. The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer. *Int J Clin Oncol.* 2011;**18**:26–32. [PubMed] [Google Scholar]

Eller, L., Merideth, K. (2016). Sonographic Detection of Metastatic Breast Cancer in the Liver. Journal of Diagnostic Medical Sonograph,. 32 (1), 44-47.

Elsaeid, Y. M., Elmetwally, D., & Eteba, S. M. (2019). Association between ultrasound findings, tumor type, grade, and biological markers in patients with breast cancer. *Egyptian Journal of Radiology and Nuclear Medicine*, *50*(1), 53. https://doi.org/10.1186/s43055-019-0048-1

Eng, L. G., Dawood, S., Sopik, V., Haaland, B., Tan, P. S., Bhoo-Pathy, N., Warner, E., Iqbal, J., Narod, S. A., & Dent, R. (2016). Ten-year survival in women with primary stage IV breast cancer. *Breast Cancer Research and Treatment*, *160*(1), 145–152. https://doi.org/10.1007/s10549-016-3974-x

Faida eka, 2016, Analisa Pengaruh Faktor Usia, Status Pernikahan dan Riwayat Keluarga terhadap Pasien Kanker Payudara di Rumah Sakit Onkologi Surabaya, Surabaya; Jurnal Manajemen Kesehatan STIKES Yayasan RS. Dr. Soetomo, Vol.2 No.1, April 2016:1-7;

Gaillard, F., & Jones, J. (2021). *Hepatic metastases*. Radiopaedia.Org. https://radiopaedia.org/articles/hepatic-metastases-1

Gong, Y., Liu, Y. R., Ji, P., Hu, X., & Shao, Z. M. (2017). Impact of molecular subtypes on metastatic breast cancer patients: A SEER population-based study. *Scientific Reports*, *7*(January), 1–10. https://doi.org/10.1038/srep45411

Heiken, J. P., Weyman, P. J., Lee, J. K., Balfe, D. M., Picus, D., Brunt, E. M., & Flye, M. W. (1989). Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. *Radiology*, *171*(1), 47–51. https://doi.org/10.1148/radiology.171.1.2538862

Heilmann T, Vondung F, Borzikowsky C, Szymczak S, Krüger S, Alkatout I, Wenners A, Bauer M, Klapper W, Röcken C, Maass N, von Karstedt S, Schem C, Trauzold A. Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients. J Mol Med (Berl). 2019 Aug;97(8):1155-1167. doi: 10.1007/s00109-019-01805-w. Epub 2019 Jun 10. PMID: 31183506.

Hwang, M., Jayakrishnan, T. T., Green, D. E., George, B., Thomas, J. P., Groeschl, R. T., Erickson, B., Pappas, S. G., Gamblin, T. C., & Turaga, K. K. (2014). Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. *European Journal of Cancer*, *50*(10), 1747–1757. https://doi.org/10.1016/j.ejca.2014.03.277

Hung, M. H. *et al.* (2014) 'Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients', *PLoS ONE*, 9(2). doi: 10.1371/journal.pone.0089389.

Jamnasi, J., Gondhowiardjo, S., Djoerban, Z., Siregar, N. C., Poetiray, E. D., & Tunggono, A. P. (2016). Faktor Risiko Terjadinya Metastasis Jauh Pada Pasien Kanker Payudara. *Radioterapi & Onkologi Indonesia*, *7*(2), 55–59.

Ji, L., Fan, L., Zhu, X., Gao, Y., & Wang, Z. (2020). A Prognostic Model for Breast Cancer With Liver Metastasis. *Frontiers in Oncology*, *10*, 1342. https://doi.org/10.3389/fonc.2020.01342

Joe, B. N. (2021) *Clinical features, diagnosis, and staging of newly diagnosed breast cancer*, *UpToDate*. Available at: https://www.uptodate.com/contents/clinical-features-diagnosis-and-staging-of-newly-diagnosed-breast-cancer%0A (Accessed: 28 August 2021).

Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010). Metastatic Behavior of Breast Cancer Subtypes. *Journal of Clinical Oncology*, *28*(20), 3271–3277. https://doi.org/10.1200/JCO.2009.25.9820

Klimov, S., Rida, P., Aleskandarany, M. *et al.* Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers. *Br J Cancer* 117, 826–834 (2017). https://doi.org/10.1038/bjc.2017.224

Kolben, T., Bardenhewer, M., Kolben, T. M., Rickerl, L., Degenhardt, T., Mahner, S., Harbeck, N., & Wuerstlein, R. (2020). Metastatic Breast Cancer: Is There a Differential Therapy Efficacy between Visceral and Non-Visceral

Metastatic Breast Cancer? *Breast Care*, *15*(5), 527–533. https://doi.org/10.1159/000504527

Komite Penanggulangan Kanker Nasional. (2016). *Panduan Penatalaksanaan Kanker Payudara*. Jakarta: Komite Penanggulangan Kanker Nasional.

Koo, J. S., Jung, W., & Jeong, J. (2010). Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. *Tumori*, *96*, 424–432.

Labellapansa, A., Muhimmah, I., & Indrayanti. (2013). Klasifikasi Citra Imunohistokimia Sel Kanker Payudara HER2 Skore 1+ dan 3+. *Seminar Nasional Informatika Medis (SNIMed) IV*, 24.

Largillier, R., Ferrero, J.-M., Doyen, J., Barriere, J., Namer, M., Mari, V., Courdi, A., Hannoun-Levi, J. M., Ettore, F., Birtwisle-Peyrottes, I., Balu-Maestro, C., Marcy, P. Y., Raoust, I., Lallement, M., & Chamorey, E. (2008). Prognostic factors in 1,038 women with metastatic breast cancer. *Annals of Oncology : Official Journal of the European Society for Medical Oncology*, *19*(12), 2012–2019. https://doi.org/10.1093/annonc/mdn424

Listyowati, I., Soetikno, R. D., & Santiana, L. (2016). Enhancement Comparison of Dendrimer Poly (Amidoamin) Nano-ParticleContrast Agent with Different Concentration and Delay Time in the Rat Liverusing Computed Tomography. *Jurnal Radiologi Indonesia*, *1*(3), 131–203.

Ma, R., Feng, Y., Lin, S., Chen, J., Lin, H., Liang, X., Zheng, H., & Cai, X. (2015). Mechanisms involved in breast cancer liver metastasis. *Journal of Translational Medicine*, *13*(1), 64. https://doi.org/10.1186/s12967-015-04250

Mamone, G., Di Piazza, A., Carollo, V. *et al.* Imaging of hepatic hemangioma: from A to Z. *Abdom Radiol* **45,** 672–691 (2020). https://doi.org/10.1007/s00261-019-02294-8

Memorial Sloan Kettering Cancer Center. (2021). *Symptoms of Liver Metastases (Secondary Liver Cancer)*. Mskcc.Org. https://www.mskcc.org/cancer-care/types/liver-metastases/symptoms-liver-metastases

Mhlanga, J.C., Evans, A.E., Doyle, S., James, J.J., Cornford, E.J., Balls, G., Chan, S.Y., Ellis, I., 2011. The prognostic significance of computerised tomography findings in women with liver metastases from breast cancer. *Breast* 20: 455–459. doi:10.1016/j.breast.2011.04.011

Natsir, M. Z., Amran, M., & Livi, H. (2019). Gambaran CT Scan atau USG Penderita Hepatoma Yang Dirawat di RSU Anutapura dan RSUD Undata Palu Periode 2015-2017. *JURNAL MEDIKA ALKHAIRAAT*, *1*(2), 61–64.

Ng, C. H., Pathy, N. B., Taib, N. A., Teh, Y. C., Mun, K. S., Amiruddin, A., Evlina, S., Rhodes, A., & Yip, C. H. (2011). Comparison of breast cancer in Indonesia and Malaysia--a clinico-pathological study between Dharmais Cancer Centre Jakarta and University Malaya Medical Centre, Kuala Lumpur. *Asian Pacific journal of cancer prevention : APJCP*, *12*(11), 2943–2946.

Noone, A. M., Cronin, K. A., Altekruse, S. F., Howlader, N., Lewis, D. R., Petkov, V. I., & Penberthy, L. (2017). Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992-2013. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, *26*(4), 632–641. https://doi.org/10.1158/1055-9965.EPI-16-0520

Ntekim A, Nufu F, Campbell O. Breast cancer in young women in Ibadan, Nigeria. Afr Health Sci. 2009;9(4):242–6.

O'Connor, S. M., & Lawton, T. J. (2015). Can Molecular Subtyping Be Used to Guide Metastatic Screening in Breast Cancer? *American Journal of Clinical Pathology*, *143*(4), 468–470. https://doi.org/10.1309/AJCPR3BFA2PHSNYD

Pearce, E. C. (2009). *Anatomi dan Fisiologi untuk Paramedis*. PT Gramedia Pustaka Utama.

Pesapane, F., Downey, K., Rotili, A., Cassano, E., & Koh, D. M. (2020). Imaging diagnosis of metastatic breast cancer. *Insights into imaging*, *11*(1), 79. https://doi.org/10.1186/s13244-020-00885-4Ramos-Vara, J. A. (2005). Technical Aspects of Immunohistochemistry. *Veterinary Pathology*, *42*(4), 405–426. https://doi.org/10.1354/vp.42-4-405

Rashid, N. S., Grible, J. M., Clevenger, C. V., & Harrell, J. C. (2021). Breast cancer liver metastasis: current and future treatment approaches. *Clinical & experimental metastasis*, *38*(3), 263–277. https://doi.org/10.1007/s10585-021-10080-4

Rice, S. C., & Bien, M. (2018). *Liver Metastasis*. Healthline.

https://www.healthline.com/health/liver-metastases

Robinson, M., Atmakusumah, T. D., Irawan, C., & Shatri, H. (2020). Profil Imunohistokimia Pasien Kanker Payudara yang Mendapat Kemoterapi Berbasis Antrasiklin di RSUD Kota Bogor. *Jurnal Penyakit Dalam Indonesia*, *6*(4), 173–177. https://doi.org/10.7454/jpdi.v6i4.345

Rosida, A. (2016). Pemeriksaan Laboratorium Penyakit Hati. *Berkala Kedokteran*, *12*(1), 123–131.

Saika K, Sobue T. Epidemiology of Breast cancer in Japan and the US.JMAJ 52(1):39-44,2009.

Sastroasmoro, S., & Ismael, S. (2011). *Dasar-dasar metodologi penelitian klinis* (4th ed.). Jakarta: Sagung Seto

Schicho, A., Pereira, P. L., Haimerl, M., Niessen, C., Michalik, K., Beyer, L. P., Stroszczynski, C., & Wiggermann, P. (2017). Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy. *Oncotarget*, *8*(42), 72613–72620. https://doi.org/10.18632/oncotarget.19997

Schoellhammer, H. F., Hsu, F., Vito, C., Chu, P., Park, J., Waisman, J., & Kim, J. (2014). Complete pathologic response of HER2-positive breast cancer liver metastasis with dual anti-HER2 antagonism. *BMC cancer*, *14*, 242. https://doi.org/10.1186/1471-2407-14-242Semelka, R. C., Brown, M. A., & Altun, E. (2015). *Abdominal-Pelvic MRI*. Wiley-Blackwell.

Sica, G. T., Ji, H., & Ros, P. R. (2000). CT and MR Imaging of Hepatic Metastases. *American Journal of Roentgenology*, *174*(3), 691–698. https://doi.org/10.2214/ajr.174.3.1740691

Sihombing M dan Aprildah Nur Sapardin. Faktor Risiko Tumor Payudara pada Perempuan Umur 25-65 Tahun di Lima Kelurahan Kecamatan Bogor Tengah. Jurnal Kesehatan Reproduksi. 2015; 5 (3): 3740

Siperstein, A. E., Berber, E., Ballem, N., & Parikh, R. T. (2007). Survival After Radiofrequency Ablation of Colorectal Liver Metastases. *Annals of Surgery*, *246*(4), 559–567. https://doi.org/10.1097/SLA.0b013e318155a7b6

Sirait A, Oemiati R, Indrawati. 2009. Hubungan kontrasepsi pil dengan tumor/kanker payudara di Indonesia. Majalah Kedokteran Indonesia 59 (8)

Smithuis, R., & Lange, E. E. de. (2015). *Liver: Segmental Anatomy*. The Radiology Assistant. https://radiologyassistant.nl/abdomen/liver/segmental-anatomy

Sopik, V., & Narod, S. A. (2018). The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. *Breast cancer research and treatment*, *170*(3), 647–656. https://doi.org/10.1007/s10549-018-4796-9

Soyer, P, Bluemke, D. A., Hruban, R. H., Sitzmann, J. V, & Fishman, E. K. (1994). Hepatic metastases from colorectal cancer: detection and false-positive findings with helical CT during arterial portography. *Radiology*, *193*(1), 71–74. https://doi.org/10.1148/radiology.193.1.8090923

Soyer, Philippe, Bluemke, D. A., & Fishman, E. K. (1994). CT During Arterial Portography for the Preoperative Evaluation of Hepatic Tumors: How, When, and Why? *AJR*, *163*, 1325–1331.

Sung, H. *et al.* (2021) 'Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries', *CA: A Cancer Journal for Clinicians*, 71(3), pp. 209–249. doi: 10.3322/caac.21660.

Suyatno, Pasaribu, E. T. (2010). *Bedah Onkologi Diagnostik dan Terapi.* Jakarta: Sagung Seto.

Szklaruk, J., Silverman, P. M., & Charnsangavej, C. (2003). Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma. *American Journal of Roentgenology*, *180*(2), 441–454. https://doi.org/10.2214/ajr.180.2.1800441

The Global Cancer Observatory. (2021). *Indonesia Fact Sheet*. https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf

The Regents of the University of California. (2021). *Liver Metastases*. Department of Surgery UCSF. https://surgery.ucsf.edu/conditions--procedures/liver-metastases.aspx

Vermeulen PB, Dirix LY, Libura J, Vanhoolst IF, Van Marck E, Van Oosterom AT (1997) Correlations of the fractions of proliferating tumor and endothelial cells in breast and colorectal adenocarcinoma is independent of tumor histiotype and microvessel density. *Microvasc Res* **54**: 88–92

Wijaya, I. G. C. P., & Manuaba, I. B. T. W. (2017). Hubungan Subtipe Imunohistokimia dengan Usia pada Pasien Kanker Payudara di RSUP Sanglah Kota Denpasar. *E-Jurnal Medika*, *6*(3), 1–5.

Wu, Q., Li, J., Zhu, S., Wu, J., Chen, C., Liu, Q., Wei, W., Zhang, Y., & Sun, S. (2017). Breast cancer subtypes predict the preferential site of distant metastases: A SEER based study. *Oncotarget*, *8*(17), 27990–27996. https://doi.org/10.18632/oncotarget.15856

Yeeravalli, R., & Das, A. (2021). Molecular mediators of breast cancer metastasis. *Hematology/Oncology and Stem Cell Therapy*, 1–15. https://doi.org/10.1016/j.hemonc.2021.02.002

Wang, R., Zhu, Y., Liu, X. *et al.* The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. *BMC Cancer* **19,** 1091 (2019). https://doi.org/10.1186/s12885-019-6311-z

Wyld, L., Gutteridge, E., Pinder, S. E., James, J. J., Chan, S. Y., Cheung, K. L., Robertson, J. F., & Evans, A. J. (2003). Prognostic factors for patients with hepatic metastases from breast cancer. *British journal of cancer*, *89*(2), 284–290. https://doi.org/10.1038/sj.bjc.6601038

Yamaguchi, T., Oura, S., Honda, M., & Makimoto, S. (2020). A Case of Hyperintense Liver Metastases of Breast Cancer in the Hepatobiliary Phase on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging. *Case reports in oncology*, *13*(2), 973–978. https://doi.org/10.1159/000508995

Zaha D. C. (2014). Significance of immunohistochemistry in breast cancer. *World journal of clinical oncology*, *5*(3), 382–392. https://doi.org/10.5306/wjco.v5.i3.382